Abstract: The present invention relates to the diagnosis of mixed lineage leukemia (MLL), acute lymphoblastic leukemia (ALL), and acute myelogenous leukemia (AML) according to the gene expression profile of a sample from an individual, as well as to methods of therapy and screening that utilize the genes identified herein as targets.
Type:
Grant
Filed:
July 17, 2002
Date of Patent:
March 14, 2006
Assignees:
Whitehead Institute for Biomedical Research, Dana-Farber Cancer Institute, Inc.
Inventors:
Todd R. Golub, Scott A. Armstrong, Stanley J. Korsmeyer
Abstract: The invention relates to a fed-batch fermentation process which uses special E. coli host/vector systems for the purpose of efficiently forming recombinant proteins, in particular recombinant antibody molecules, preferably antibody fragments such as miniantibodies. Under the given conditions, the E. coli cells are able to grow at a maximum specific growth rate up to very high cell densities. After the recombinant product formation has been switched on, it is only the formed product which restricts growth; there is no growth restriction due to substrates or metabolic by-products. High space-time yields of recombinant proteins can be achieved in this manner.
Type:
Grant
Filed:
November 16, 1998
Date of Patent:
June 25, 2002
Assignee:
Merck Patent Gesellschaft
Inventors:
Wolfgang Strittmatter, Siegfried Matzku, Dieter Riesenberg, Uwe Horn, Uwe Knüpeer, Marian Kujau, Rolf Wenderoth, Andreas Plückthun, Anke Krebber